A low-cost gout medication may significantly reduce the risk of heart attacks and strokes in people with established cardiovascular disease, according to a comprehensive Cochrane systematic review published in February 2025. The findings, based on analysis of 12 randomized controlled trials involving nearly 23,000 participants, suggest that low-dose colchicine offers a potentially affordable prevention strategy for millions living with heart disease worldwide.
Study Design and Participant Profile
Researchers systematically evaluated evidence from trials in which participants with a history of cardiovascular disease, prior heart attack, or stroke took colchicine—typically at doses of 0.5 mg once or twice daily—for at least six months. The study population was predominantly male (approximately 80%), with average ages ranging from 57 to 74 years. About half of participants received colchicine as an addition to their standard cardiovascular medications, while the remainder received either a placebo or continued standard care alone.
This meta-analytic approach allowed researchers to pool data across multiple independent trials, strengthening the statistical power to detect clinically meaningful effects that individual studies might miss.
Significant Reductions in Cardiovascular Events
The analysis found high-certainty evidence that low-dose colchicine reduces the risk of myocardial infarction and stroke. For every 1,000 individuals treated with colchicine, approximately 9 heart attacks and 8 strokes were prevented compared with those receiving placebo or standard care alone. In practical terms, among 200 people with cardiovascular disease—where roughly seven heart attacks and four strokes would be expected—colchicine use could prevent approximately two cases of each event.
A separate meta-analysis of 10 randomized clinical trials published in the European Heart Journal found that addition of colchicine to standard medical treatment reduced the overall risk of major adverse cardiovascular events (MACE) by 27 percent, with a number needed to treat of 52. The drug also showed particular benefit in reducing myocardial infarction risk by 17 percent and the need for coronary revascularization procedures by 21 percent.
Safety Profile and Gastrointestinal Considerations
Importantly, the Cochrane review found no increase in serious adverse events among colchicine users. However, mild and transient gastrointestinal side effects—including diarrhea and nausea—were more common in the colchicine group, though these typically resolved quickly and did not lead to treatment discontinuation in most cases.
The absence of serious safety signals is particularly significant given colchicine’s long history of clinical use. The drug has been employed in medical practice for centuries, originally derived from the autumn crocus plant, before being synthesized and standardized for pharmaceutical use.
Anti-Inflammatory Mechanism and Cardiovascular Disease
Cardiovascular disease, particularly atherosclerotic forms affecting the heart and blood vessels, is increasingly understood as fundamentally driven by chronic, low-level inflammation. This inflammatory process promotes the rupture of arterial plaques, which can trigger blood clots leading to heart attacks and strokes. Colchicine works by inhibiting inflammasome activation and reducing the production of inflammatory signaling molecules, potentially addressing this underlying pathophysiological mechanism.
This understanding represents a shift in cardiovascular prevention strategy—moving beyond traditional approaches focused solely on cholesterol reduction and blood pressure control to target the inflammatory component of disease progression.
Limitations and Unanswered Questions
The Cochrane authors note important gaps in current evidence. Moderate-certainty findings indicate that colchicine probably does not reduce overall mortality from any cause or cardiovascular-specific death. Additionally, the trials did not demonstrate a clear benefit for coronary revascularization procedures, and effects on quality of life and hospital admissions remain unknown because existing studies did not measure these outcomes.
Researchers emphasize that longer-term studies involving larger populations are needed to definitively establish whether colchicine influences survival rates and to better characterize its effects on functional health outcomes and healthcare utilization.
Public Health and Clinical Implications
With cardiovascular disease remaining the leading cause of death globally, colchicine presents a potentially transformative secondary prevention tool. The drug’s established safety record, minimal cost, widespread availability, and oral dosing make it particularly attractive for implementation in diverse healthcare settings—from high-resource countries to low- and middle-income regions where access to newer, expensive cardiovascular therapies remains limited.
According to the World Health Organization, cardiovascular and other noncommunicable diseases account for the majority of preventable deaths worldwide. Effective, affordable secondary prevention strategies are essential to reducing this burden.
The evidence supporting colchicine also exemplifies the value of academic research in repurposing existing medications for new therapeutic applications. Unlike traditional pharmaceutical development, which requires extensive investment in novel drug synthesis and regulatory approval, this approach accelerates the pathway from scientific discovery to clinical practice while minimizing development costs.
Current Clinical Integration and Next Steps
Several professional medical societies have begun updating clinical guidelines to reflect these findings. For patients with established cardiovascular disease on optimal medical therapy who experience recurrent events or have contraindications to other preventive medications, low-dose colchicine represents an evidence-supported option worth discussing with their healthcare provider.
Ongoing research continues to explore colchicine’s effects in specific cardiovascular subgroups, its interaction with other medications, optimal dosing strategies, and long-term adherence patterns. Understanding whether benefits extend to primary prevention in high-risk but asymptomatic individuals remains an open question requiring dedicated investigation.
For readers seeking more information on cardiovascular disease prevention and treatment advances, read more on Globally Pulse Health.
